Aksiyal spondiloartrit ve santral sensitizasyon ilişkisi
Küçük Resim Yok
Tarih
2024
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
İnönü Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Aksiyal spondiloartrit (AksSpA) hastalarında santral sensitizasyon (SaS) sıklığını, bu durum ile ilişkili olabilecek komorbiditelerin neler olduğunu, AksSpA hastalarında SaS' ın hastalığa ait klinik parametreler ile ilişkisini araştırmayı amaçladık. Gereç ve yöntem: Çalışmamıza 100 AksSpA hastası ve 100 kontrol hastası dahil edildi. Gruplarda santral senstizasyon ölçeği (SaSÖ) ile santral sensitizasyon (SaS) varlığı araştırıldı. Hasta grubunda hastalık aktivitesi (BASDAI, ASDAS-CRP), fonksiyonel durum (BASFI), hareket kısıtlılığı (BASMI), yaşam kalitesi (ASQoL), uyku kalitesi (Jenkins uyku skalası), depresyon (BDÖ) ve anksiyete (BAÖ), nöropatik ağrı (DN4), fibromyalji (FIRST) ve huzursuz bacak sendromu varlığı değerlendirildi. Kontrol grubunda ise uyku kalitesi (Jenkins uyku skalası), depresyon (BDÖ) ve anksiyete (BAÖ), nöropatik ağrı (DN4), fibromyalji (FIRST) ve huzursuz bacak sendromu varlığı değerlendirildi. Hasta ve kontrol grubu SaSÖ puanlarına göre SaS olan ve SaS olmayan olarak gruplara ayrılarak değerlendirilen parametreler açısından karşılaştırıldı. Bulgular: AksSpA ve kontrol grubu sosyodemografik veriler açısından benzerlik göstermektedir. AksSpA hastalarında 16, kontrol grubunda ise 14 kişide SaS saptanmıştır. SaS varlığı açısından her iki grup arasında anlamlı farklılık bulunmamıştır (p >0,05). SaS olan AksSpA hastalarının BASDAI, ASDAS-CRP, BASFI, BASMI, ASQoL, MASES, BDÖ, BAÖ ,DN4, Jenkins uyku skalası, FIRST skorları SaS olmayan gruba göre daha yüksek olarak hesaplandı (p< 0,05). Kontrol grubunda ise SaS olanların BDÖ, BAÖ, FIRST, DN4, Jenkins uyku skalası skorları SaS olamayanlara göre daha yüksek olarak bulundu (p<0,05). Kontrol grubu ile hasta grubu arasında depresyon, anksiyete, fibromyalji ve nöropatik ağrı sıklığı ve uyku kalitesi açısından anlamlı farklılık görülmedi (p > 0,05). Sonuç: AksSpA hastalarında anksiyete, depresyon, fibromyalji, nöropatik ağrı gibi komorbiditelerin varlığında SaS sıklığının artmış olduğu görülmektedir. Antiinflamatuar tedaviye rağmen kronik ağrıları devam eden hastaların SaS açısından değerlendirilmesi ve buna göre tedavi planları oluşturulması gereksiz tedavi değişikliklerini önleyebilir. Anahtar sözcükler: Aksiyal spondiloartrit, Santral sensitizasyon, Santral sensitizasyon ölçeği
Objective: We aimed to investigate the frequency of central sensitization (CS) in patients with axial spondyloarthritis (AxSpA), the comorbidities that may be associated with this condition, and the relationship between CS and clinical parameters of the disease in AxSpA patients. Materials and methods: Our study included 100 AxSpA patients and 100 control patients. The presence of central sensitization (CS) was investigated with the central sensitization inventory (CSI) in the groups. Disease activity (BASDAI, ASDAS-CRP), functional level (BASFI), mobility limitation (BASMI), quality of life (ASQoL), sleep quality (Jenkins sleep scale), depression (BDI) and anxiety (BAI), neuropathic pain (DN4), fibromyalgia (FIRST) and presence of restless legs syndrome were evaluated in the patient group. In the control group, sleep quality (Jenkins sleep scale), depression (BDI) and anxiety (BAI), neuropathic pain (DN4), fibromyalgia (FIRST) and presence of restless legs syndrome were evaluated. Patients were divided as the ones with and without CS according to the central sensitization inventory (CSI) and the results were compared. Results: AxSpA and control group were similar in terms of sociodemographic data. CS was detected in 16 of 100 AxSpA patients. CS frequency was similar in AxSpA and control group (p> 0,05). AxSpA patients with CS had higher BASDAI, ASDAS-CRP, BASFI, BASMI, ASQoL, MASES, BDI, BAI, DN4, Jenkins sleep scale, FIRST scores compared to the group without CS (p<0,05). In the control group, those with CS had higher BDI, BAI, FIRST, DN4, Jenkins sleep scale scores than those without CS (p <0.05). The frequency of depression, anxiety, fibromyalgia and neuropathic pain was similar in the control group and the patient group (p> 0.05). Conclusion: It was observed that the frequency of CS increased in the presence of comorbidities such as anxiety, depression, fibromyalgia, and neuropathic pain in patients with AxSpA. Evaluation of patients with persistent chronic pain despite anti-inflammatory treatment in terms of CS and formulation of treatment plans may prevent unnecessary treatment changes. Key words: Axial spondyloarthritis, Central sensitization, Central sensitization inventory
Objective: We aimed to investigate the frequency of central sensitization (CS) in patients with axial spondyloarthritis (AxSpA), the comorbidities that may be associated with this condition, and the relationship between CS and clinical parameters of the disease in AxSpA patients. Materials and methods: Our study included 100 AxSpA patients and 100 control patients. The presence of central sensitization (CS) was investigated with the central sensitization inventory (CSI) in the groups. Disease activity (BASDAI, ASDAS-CRP), functional level (BASFI), mobility limitation (BASMI), quality of life (ASQoL), sleep quality (Jenkins sleep scale), depression (BDI) and anxiety (BAI), neuropathic pain (DN4), fibromyalgia (FIRST) and presence of restless legs syndrome were evaluated in the patient group. In the control group, sleep quality (Jenkins sleep scale), depression (BDI) and anxiety (BAI), neuropathic pain (DN4), fibromyalgia (FIRST) and presence of restless legs syndrome were evaluated. Patients were divided as the ones with and without CS according to the central sensitization inventory (CSI) and the results were compared. Results: AxSpA and control group were similar in terms of sociodemographic data. CS was detected in 16 of 100 AxSpA patients. CS frequency was similar in AxSpA and control group (p> 0,05). AxSpA patients with CS had higher BASDAI, ASDAS-CRP, BASFI, BASMI, ASQoL, MASES, BDI, BAI, DN4, Jenkins sleep scale, FIRST scores compared to the group without CS (p<0,05). In the control group, those with CS had higher BDI, BAI, FIRST, DN4, Jenkins sleep scale scores than those without CS (p <0.05). The frequency of depression, anxiety, fibromyalgia and neuropathic pain was similar in the control group and the patient group (p> 0.05). Conclusion: It was observed that the frequency of CS increased in the presence of comorbidities such as anxiety, depression, fibromyalgia, and neuropathic pain in patients with AxSpA. Evaluation of patients with persistent chronic pain despite anti-inflammatory treatment in terms of CS and formulation of treatment plans may prevent unnecessary treatment changes. Key words: Axial spondyloarthritis, Central sensitization, Central sensitization inventory
Açıklama
Anahtar Kelimeler
Romatoloji, Rheumatology
